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LRRK2, the gene encoding the multidomain kinase Leucine-Rich Repeat Kinase 2 (LRRK2), has been linked
to familial and sporadic forms of Parkinson’s disease (PD), as well as cancer, leprosy and Crohn’s disease,
establishing it as a target for discovery therapeutics. LRRK2 has been associated with a range of cellular
processes, however its physiological and pathological functions remain unclear. The most prevalent
LRRK2 mutations in PD have been shown to affect macroautophagy in various cellular models while a role
in autophagy signalling has been recapitulated in vivo. Dysregulation of autophagy has been implicated in
PD pathology, and this raises the possibility that differential autophagic activity is relevant to disease
progression in PD patients carrying LRRK2 mutations. To examine the relevance of LRRK2 to the regula-
tion of macroautophagy in a disease setting we examined the levels of autophagic markers in the basal
ganglia of G2019S LRRK2 PD post-mortem tissue, in comparison to pathology-matched idiopathic PD
(iPD), using immunoblotting (IB). Significantly lower levels of p62 and LAMP1 were observed in
G2019S LRRK2 PD compared to iPD cases. Similarly, an increase in ULK1 was observed in iPD but was
not reflected in G2019S LRRK2 PD cases. Furthermore, examination of p62 by immunohistochemistry
(IH) recapitulated a distinct signature for G2019S PD. IH of LAMP1, LC3 and ULK1 broadly correlated with
the IB results. Our data from a small but pathologically well-characterized cases highlights a divergence
of G2019S PD carriers in terms of autophagic response in alpha-synuclein pathology affected brain
regions compared to iPD.
 2018 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Coding mutations in LRRK2 gene on chromosome 12 are associ-
ated with familial Parkinson’s disease, with non-coding variation at
the LRRK2 locus also linked to idiopathic Parkinson’s (reviewed in
Paisan-Ruiz et al., 2013). While the role of LRRK2 in diseaseremains unclear, a number of different cellular functions have been
attributed to the protein (Wallings et al., 2015). LRRK2 has been
implicated in vesicular trafficking pathways, endocytosis andmito-
chondrial homeostasis, with recent studies suggesting that mutant
LRRK2 can alter cellular macroautophagy signaling (Wallings et al.,
2015). In terms of the wide range of proposed LRRK2 functions, it is
not yet known if these should be considered as cell/tissue specific
associations, and which are relevant to the disease process of PD
(Lewis and Manzoni, 2012).
Aberrant protein aggregation is a common theme in neurode-
generative diseases, and regulation of protein degradation by
autophagic/lysosomal processes has been implicated in the neu-
ropathology of these disorders. Alpha-synuclein (a-Synuclein), a
central player in the etiology of PD and the predominant con-
stituent of Lewy bodies, is degraded by macroautophagy and
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Cytoplasmic a-synuclein inclusions impair macroautophagy and
are resistant to degradation in culture (Tanik et al., 2013). In turn,
a-synuclein carrying the PD mutation A53T has been shown to
induce mitophagy in neurons mediating toxicity (Choubey et al.,
2011). Additionally, the lysosomal markers LAMP2A and hsc70
are reduced in the substantia nigra (s.nigra) pars compacta and
amygdala of PD brains compared to age-matched controls suggest-
ing that autophagy dysregulation is concomitant with a-synuclein
pathology in PD (Alvarez-Erviti et al., 2010). This highlights the
potential of targeting autophagy to restore physiological a-
synuclein turnover as a therapeutic approach (Rubinsztein et al.,
2012).
Autophagy is the key cellular process mediating digestion of
damaged organelles and proteins as well as the content of vesicles
following endocytosis and phagocytosis by lysosomal proteases.
Macroautophagy, the most studied form of autophagy, involves
the delivery of cargo to lysosomes via double-membrane phago-
phores and is initiated by phosphorylation events on factors of
the ULK1 (Unc Like Kinase 1) complex (Mizushima, 2010). Cellular
stress including nutrient starvation, low ATP or heat-shock can
induce inhibition of the mTOR complex and activation of AMPK.
These changes modulate the phosphorylation state of ULK1 thus
mediating its activation (Kim et al., 2011), resulting in induction
of macroautophagy initiated by membrane nucleation and
autophagosome formation. LC3 (microtubule-associated pro-
tein1A/1B light chain3) is a commonly used cellular marker for
macroautophagy, with cytosolic LC3-I lipidated to LC3-II and
recruited to autophagosomal membranes where it serves as a
receptor for selective macroautophagy. LC3-II forms a complex
with cargo proteins including p62, which in turn is involved in
recruiting substrates to the nascent autophagosome mediating
degradation (Klionsky et al., 2016).
A substantial body of literature suggests that LRRK2 is involved
in the regulation of autophagy both in vivo and in vitro (Dodson
et al., 2014; Tong et al., 2012; Lynch-day et al., 2012). LRRK2 is
expressed in several different tissues and cell types and within
the mammalian brain LRRK2 has higher expression in dopamine
innervated regions (Galter et al., 2006). Immunocytochemical and
cell fractionation studies suggest that LRRK2 is predominantly
cytosolic, but can also be found to be associated with membranes
of synaptic vesicles, endosomes and lysosomes at least in the
rodent brain (Biskup et al., 2006). Ferree and co-workers, using a
systems biology approach, observed that genes linked to autop-
hagy exerted a strong impact on dopaminergic neuron survival in
c.elegans overexpressing WT-LRRK2 (Ferree et al., 2012). Stimula-
tion of TLR4 receptor or inhibition of mTOR using rapamycin
resulted in translocation of LRRK2 to membranes and association
with autophagosomes in immune cells (Schapansky et al., 2014).
Knockdown of endogenous LRRK2 decreased autophagic flux in
monocytes (Schapansky et al., 2014), and loss of LRRK2 in mice
results in abnormal kidney development with accumulation of
the autophagy markers LC3-II and p62. This was accompanied by
alterations in protein degradation, accumulation of a-synuclein
and protein carbonyls, and apoptotic cell death (Tong et al., 2010,
2012). It has previously been shown that inhibition of LRRK2
kinase activity using specific inhibitors modulates macroau-
tophagy in cells (Manzoni et al., 2013a, 2016; Saez-Atienzar
et al., 2014) and that pathogenic mutations in the ROC-COR-
kinase domains causes alterations in autophagy and lysosomal
markers in patient fibroblasts (Manzoni et al., 2013b; Pedro
et al., 2013). In a separate study, it was demonstrated that
dopaminergic neurons differentiated from sporadic and familial
LRRK2 PD iPSc showed accumulation of autophagic vacuoles
(Sánchez-Danés et al., 2012). Therefore, it is quite plausible that
LRRK2 is involved in PD pathogenesis through its effect on cellularautophagy pathways (Manzoni and Lewis, 2017). Whether autop-
hagy is altered in the context of LRRK2 mutations in human brain
tissue has not, to date, been investigated.
The aim of this study is to test whether alterations in macroau-
tophagy observed in cellular models upon manipulation of LRRK2
are mirrored by changes in autophagy/lysosomal markers in brain
tissue from patients with LRRK2 associated PD. To this end we have
examined levels of macroautophagy markers in post-mortem tis-
sue from the basal ganglia of PD patients carrying the LRRK2
G2019S mutation and compared that with pathology-matched
idiopathic PD and control tissue using immunoblot (IB) and quan-
titative reverse transcription polymerase chain reaction (qRT-PCR).
Cellular expression was established using immunohistochemistry
(IH). We observed significantly lower p62 levels in G2019S PD
samples compared to iPD and a trend of lower LC3II levels. ULK1
protein levels showed variation with significantly greater levels
in iPD compared to control cases, while this was not reflected in
the G2019S samples. Significantly lower levels of the lysosomal
marker LAMP1 (lysosomal associated membrane protein1) were
observed in G2019S PD compared to iPD. The qRT-PCR and IH data
of the 4 autophagy related markers are broadly in line with the IB
data which reflect alterations in autophagy processes in G2019S PD
brains compared to iPD, and provide support for a possible role of
LRRK2 in dysregulation of protein degradation and pathology.
2. Results
2.1. Protein levels of macroautophagy markers
In order to investigate whether autophagy is dysregulated in
G2019S PD brain, we compared tissue from four G2019S PD cases
to five pathology-matched iPD and five control cases. Tissue from
the basal ganglia was used that is impacted by dopaminergic nerve
terminal loss and a-synuclein pathology in PD. We examined the
relative levels of four autophagy-markers as an indication of steady
state autophagic activation. To control for a possible effect of post-
mortem delay (PMD) on the levels of these markers, one-way
ANCOVA using PMD as a covariate was used for the statistical anal-
ysis. The cumulative demographic details of these cases are pre-
sented in Supplementary Table S1 and are identical to the cases
reported before (Mamais et al., 2013). The processed/lipidated
form of LC3, LC3II, was examined in the SDS-soluble fractions pro-
duced by differential fractionation, as that is predominantly
enriched for membrane-attached moieties. LC3II levels did not dif-
fer significantly between G2019S, iPD and control cases when con-
trolling for PMD (Fig. 1A, B). The G2019S PD cases displayed higher
LC3 variance with levels similar to control cases.
p62 is a ubiquitin-binding scaffold protein that is degraded
through autophagy and plays a role in tagging cargos for degrada-
tion (Bjørkøy et al., 2009). p62 levels were found to be significantly
upregulated in iPD but not in G2019S PD, when compared to con-
trol cases after controlling for PMD (Fig. 1C, D). This may indicate
accumulation of p62 in iPD reflecting an impairment in autophagy.
Furthermore, these data may also suggest an upregulation of
macroautophagy and increase in substrates tagged for degradation
by p62, as a response to neurodegeneration, which would be con-
sistent with the trend towards increased LC3-II in the iPD samples.
The kinase ULK1 is a key regulator of the induction of macroau-
tophagy, and is phosphorylated at S758 by mTOR under conditions
of nutrient sufficiency, acting to inhibit the activity of this kinase
and thereby the induction of autophagy (Kim et al., 2011). No sig-
nificant alterations were seen in S758 phosphorylation of ULK1,
while total ULK1 levels were significantly increased in iPD but
not in G2019S PD, when compared to control cases (Fig. 1C, E, F).
LAMP1 is a lysosomal transmembrane protein involved in lyso-
somal integrity and acidification of the lysosomal lumen. Newly
Fig. 1. Autophagic markers are altered in G2019S PD brain. Levels of autophagic markers (5% SDS supernatant) were analysed in G2019S PD basal ganglia and compared to
pathology-matched iPD and controls. LC3-II showed high variance and no significant divergence in G2019S compared to iPD and controls (A, B). p62 showed significantly
higher levels in iPD compared to G2019S PD and a trend towards higher levels compared to controls (C, D). ULK1 levels were increased in iPD compared to controls (C, F) while
LAMP1 was significantly lower in G2019S PD samples compared to iPD and controls (C, G). Statistical analysis was performed using ANCOVA with PMD as a covariate
(ANCOVA; *p < 0.05; n = 4 cases: G2019S PD; n = 5 cases: iPD, n = 5 cases: Controls; LC3II/actin, F(2,10) = 1.8, P = 0.215; pULK1/ULK1, F(2,10) = 2.1, P = 0.174; p62/actin, F
(2,10) = 5.5, P = 0.025; ULK1/actin, F(2,10) = 5.7, P = 0.023; LAMP1/actin, F(2,10) = 4.7, P = 0.037). Relative mRNA levels of the 4 autophagy markers from basal ganglia were
measured using qRT-PCR are shown (H-K).
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where it regulates lysosomal motility and lysosome-phagosome
fusion (Saftig and Klumperman, 2009). LAMP1 showed a significant
decrease in G2019S PD cases compared to idiopathic PD, after con-
trolling for PMD (Fig. 1C, G).
2.2. mRNA levels of autophagy proteins
We also analysed mRNA transcript levels of the four autophagy
markers p62, Lamp1, LC3 and ULK1 in tissue from the basal gangliaby qPCR. We observed varied expression levels across the three
sample cohorts and a general trend parallel to the protein findings.
LC3B did not show a difference between the sample groups while
p62 showed a trend towards an increase in iPD compared to
G2019S and control samples which reflects our findings on protein
analysis (Fig. 1E, I). ULK1 mRNA levels showed a wide spread
across cases with a trend of lower levels in G2019S cases while
LAMP1 expression was significantly lower in iPD compared to con-
trol samples with a similar but not significant trend in G2019S
samples (Fig. 1J, K). The divergence we observe between the trends
78 A. Mamais et al. / Brain Research 1701 (2018) 75–84in protein and mRNA transcript levels in the autophagic markers
analysed may be due to inherent differences and limitations of
the corresponding techniques, different effect of storage conditions
in the integrity or mRNA and protein and lastly actual biological
differences between transcript and protein abundance (Maier
et al 2009) that in our case may reflect post-translational modifica-
tions that modulate protein stability and degradation.
2.3. Immunostaining of the macroautophagy markers p62, LAMP1,
LC3, ULK1
Our data support a possible alteration of the autophagy flux in
LRRK2 PD. The divergent autophagic signature detected in
G2019S PD compared to idiopathic PD cases is interesting consid-Fig. 2. Regional p62 inclusions in control, iPD and G2019S LRRK2 cases as determined
G2019S cases but not in controls (A-C). Some oligodendroglial inclusions (Black arrows
medium spiny neurons in basal ganglia of both iPD and G2019S cases (E, F). In amygdala
seen in a G2019S case (I). Cortical LBs immunopositive for p62 were also observed in fr
negative for p62 aggregates (A, D, G, J). Scale bar represents 10 lm in all except it is 30 lm
in iPD and G2019S cases (*** denotes P < 0.001 Mann-Whitney U test) with the lines repering the cases have been matched for pathology severity. There-
fore, we next sought to compare the cellular distribution of the
autophagic markers LAMP1, LC3, ULK1 and p62 in controls, iPD
and G2019S-LRRK2 PD in brain regions affected by a-synuclein
pathology using IH. The antibodies used here have all been tested
in mammalian cells for cellular localization (Licon-Munoz et al.,
2017; Ahmed et al., 2010; Schmitz et al., 2016; Liu et al., 2018).
Our negative controls in which either primary or secondary anti-
body was omitted gave no appreciable immunopositivity on tissue
sections.
2.3.1 p62 IH: In formalin-fixed tissue, we detected moderate to
high numbers of pale bodies (PBs) and Lewy bodies (LBs) positive
for p62 in both iPD and G2019S LRRK2 mutation cases (Fig. 2). A
higher number of p62 positive dystrophic neurites, Lewy neuritesby immunohistochemistry. p62 immunopositive LBs were found both in iPD and
) were immunopositive for p62 in the nigra (B, C). p62 deposits were also noted in
, extracellular p62 granular deposits were noted (H) and abundant cortical type LBs
ontal cotex of both PD subgroups (K, L). For all the regions, control cases remained
in H. Consensus read outs of LB and LN scores in four regions (combined) analysed
resenting the mean scores.
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inclusions immunopositive for p62 were detected in the s. nigra
of both G2019S PD and iPD. Neuronal cytoplasmic staining was
present in the majority of dopaminergic neurons in iPD and
G2019S LRRK2 cases. In contrast, control cases did not show p62
immunopositivity in the melanized dopaminergic neurons. The
p62 positive inclusions were similar in appearance in both PD
cohorts. In basal ganglia and amygdala, higher numbers of p62
positive extracellular deposits were noted in iPD compared to
G2019S cases. We detected p62-positive granulovacuolar degener-
ation bodies GVD’s in the amygdaloid cortex of both affected
cohorts with higher numbers presented in G2019S PD. Small num-
bers of p62 positive neurofibrillary tangles and oligodendroglial
inclusions were also observed in some cases, which is likely to be
incidental pathology. Semiquantitative scores of p62 inclusions
are summarised in Table 1. The combined scores of LBs and LNs
from all four regions were significantly higher in iPD compared
to G2019S cases (P < 0.001 Mann-Whitney U) (Fig. 2M).
2.3.2 LAMP-1 IH: demonstrated punctate deposits within some
neurons and in glial cells. Majority of glial staining morphologically
appeared to associate with microglia. There was some accumula-
tion of cytosolic LAMP-1 immunoreactivity (IR) within dopaminer-
gic neurons in the s. nigra in iPD and also in G2019S-LRRK2 cases
compared to controls. There was some upregulation of LAMP-1
expression associated with frontal cortical neurons in both the
PD subtypes tested. Frontal cortical neurons however expressed
higher levels of LAMP-1 compared to controls. Glial cells displayed
strong immunoreactivity for LAMP-1 in iPD cases (Fig. 3). Immuno-
histochemistry scores are presented in Fig. 3. The IH scores were
significantly higher for iPD compared to control cases in both s.ni-
gra and frontal cortex (Kruskall Wallis test with Dunn’s multiple
comparison test). There were no LBs or LNs positive for LAMP-1.
2.3.3 LC3-IH: The antibody recognises both LC3I and II. In all
cases examined, substantial population of cortical neurons consti-
tutively exhibited LC3 IR within the cytoplasm at varying intensi-
ties. DAergic neurons showed lower LC3 levels. LBs and LNs
remained negative for LC3 IR. Some cortical neurons demonstrated
higher perinuclear LC3 staining compared to the processes. Glial
processes were negative for LC3 IR although some glial nuclei were
moderately positive for LC3 IR (Fig. 3). LB’s and LNs were unstained
for LC3 in all PD cases examined. Higher LC3 scores were recorded
in both s.nigra and frontal cortex although these were not statisti-
cally significant.
2.3.4 ULK-1IH: ULK1-IR was apparent in the cytoplasm of some
neurons from the s. nigra and frontal cortex of controls, iPD and
G2019S. In controls, ULK-1 IR was also seen in neuronal processes
in pyramidal neurones of frontal cortex and also DAergic neuronsTable 1
Summary of p62 staining.
Cases Regions Types of p62 inclusions/staining
PBs/LBs dystrophic neurites
and LN’s
N
st
Control cases 1–5 s. nigra – – –
Basal ganglia – – 
Amygdala – – 
Frontal cortex – – 
iPD cases 1–5 s. nigra ++ to +++ ++ to +++ +
Basal ganglia ++ to +++ ++ to +++ 
amygdala ++ to +++ ++ to +++ 
Frontal cortex + to ++ + to ++ 
G2019S cases 1–4 s. nigra + to +++ + to ++ +
Basal ganglia + to ++ + 
Amygdala + to +++ + 
Frontal cortex + to ++ + 
Key:  (no inclusions/staining); + = occasional inclusions/staining ; ++ = moderate inclu
PBs = Pale bodies; LBs = Lewy bodies, LNs = Lewy neurites; NFTs = Neurofibrillary tanglein the s. nigra, which were not observed in PD neurons in PD cases.
Reactive astrocytes were positive for ULK-1 IR and were more
apparent in the white matter-grey matter border of PD cases
(Fig. 3). ULK1 scores in the s. nigra were very similar in all three
case groups, however in the frontal cortex, ULK1 scores were sig-
nificantly higher in iPD compared to controls (P < 0.05; Kruskall
Wallis test with Dunn’s multiple comparison).
3. Discussion
Autophagy comprises a range of highly conserved cellular pro-
cesses that contribute to protein homeostasis. Autophagic activity
decreases with age with dysregulation of macroautophagy and
chaperone-mediated autophagy reported in a wide spectrum of tis-
sues and diseases (Cuervo and Dice, 2000; Terman, 1995). In neu-
rodegenerative disease, a number of dysregulated signaling events
related to protein turnover and degradation have been reported.
Mutations in PINK1 and PRKN, coding for the kinase PINK1 and
the ubiquitin ligase Parkin respectively, are associated with
autosomal-recessive PD and act to disrupt mitophagy – leading
to reduced clearance of damaged mitochondrial and hence cell
death (Yamano et al., 2016). Furthermore, a number of studies
have proposed that basal levels of autophagy are important for
the clearance of a-synuclein, thus limiting intracellular oligomer-
ization and formation of aggregates (Vogiatzi et al., 2008). Interest-
ingly, studies on autophagic markers in the context of
neurodegenerative disease namely, Dementia with Lewy bodies
(DLB) has shown some alterations compared to controls (Gurney
et al., 2018, Higashi et al 2011).
In this study, we investigated markers of macroautophagy in
brain tissue from iPD, G2019S LRRK2 PD and control cases.
Specifically, we examined LC3-II, p62, phosphorylated ULK1 and
LAMP1 levels in the basal ganglia of post-mortem brain tissue. Pre-
vious work from our group has shown that mutations in LRRK2
lead to dysregulation of the autophagic response to starvation.
Fibroblasts from patients carrying the R1441C, Y1699C or
G2019S mutations show an attenuated response to macroau-
tophagy activation by starvation compared to WT cells, as indi-
cated by modulation of LC3 I/II levels upon cell starvation
(Manzoni et al., 2013b). In this study, we observed a high variance
of LC3-II in G2019S and no significant difference to iPD or controls.
A larger number of cases would need to be analyzed to yield a more
granular understanding of LC3-II changes in G2019S PD.
Our results indicate higher p62 levels in iPD compared toG2019S
cases and a trend of higher levels compared to control tissue, reflect-
ing either accumulation of un-degraded cargo or an increase in the
basal levels of cargo processing. p62 levels in the G2019S PDeuronal cytoplasmic
aining
Extracellular granular
staining
GVDs Coiled bodies
and NFTs
– – +
to +  to + – –
to + – – –
to + – – +
to +++ ++ to +++ – +
to ++ ++ – –
to ++ ++ to +++ ++ +
to ++ + to ++ + +
to +++ + to ++ – +
to ++ + – –
to ++ + to ++ + to +++ –
to + + to ++ + to ++ +
sions/staining ; +++ = large number of inclusions/.
s.
Fig. 3. Representative images of immunohistochemistry of LAMP1, LC3 and ULK1 from s.nigra and frontal cortex of controls, iPD and G2019S_LRRK2 PD postmortem brains.
A-F is Lamp1; G-L is LC3; M-R is ULK1. The scale bar is 20 lm in A, B,C, F, M, N, O and R and 40 lm in D-L, and P, Q. Black arrow in N points to s.nigra LBs negative for ULK1.
Inset in Q shows white matter glia positive for ULK1. Corresponding semiquantitative IH scores from neurons and glia from controls, iPD and G2019S cases are shown for s.
nigra and frontal cortex (f.cortex). Graphs represent consensus scores for each autophagy marker with the line representing the mean scores. Statistical significance of scores
between the case groups were tested using Kruskall-Wallis statistic with Dunn’s post-hoc test (* denotes P < 0.05).
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ROC-COR domain mutations (R1441G and Y1699C) show fewer
p62-positive puncta following starvation (Manzoni et al., 2013b).
In a different study, G2019S PD fibroblasts were reported to have
increased basal LC3-II and lower p62 levels compared to control
cells (Pedro et al., 2013). The data presented here are consistent
with cell studies suggesting that an impairment inmacroautophagyas seen in PD (Wang et al., 2016) may be distinct in LRRK2 genetic
PD cases. Intriguingly, our data suggest a decrease in LAMP1 levels
in the G2019S PD tissue compared to both iPD and pathologically
normal control samples, further highlighting a divergence in patho-
biology between LRRK2 PD and iPD. These data have been summa-
rized in Fig. 4. Winslow and colleagues have previously shown that
a-synuclein can dysregulate Atg9 localization and impair
Fig. 4. Schematic of macroautophagy activation and changes observed in post-
mortem iPD and G2019S PD cases. Upstream AMPK and mTOR -dependent signals
mobilise ULK1 and a spectrum of Atg factors as a response to oxidative stress,
nutrient starvation and other cellular stresses. Initial stages of autophagosome
formation see LC3-II recruitment to the autophagosome membrane followed by
docking of p62. This results in autophagosome closure and engulfment of cargoes to
be degraded following fusion with lysosomes. Lower levels of p62 observed in
G2019S PD compared to iPD may reflect poor p62 production with accumulation of
undegraded cargo or abnormal increase in the speed of autophagosome/p62
degradation. LAMP1 levels were increased in iPD compared to G2019S PD
suggesting a dysregulation of trafficking events that mediate sequestration of
lysosomal components in genetic PD cases.
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(Winslow et al., 2010). We have previously shown divergent solu-
bility and aggregation properties of a-synuclein in the G2019S PD
cases examined here compared to pathology-matched iPD cases
(Mamais et al., 2013). It is a plausible hypothesis that a difference
in the biochemical properties of a-synuclein may underlie a diver-
gence in macroautophagy events accompanying neuropathology.
To test this hypothesis we performed a linear regression analysis
that showed a significant correlation between LAMP1 levels and
aggregated a-synuclein levels in the urea fraction of iPD samples,
while the G2019S samples showed a significant correlation of both
p62 and ULK1 levels with aggregated a-synuclein (Supplementary
Table S2. Lastly, we tested whether disease duration may explain
any differences we observe in autophagic markers. A significant
inverse correlation between p62 levels and disease duration was
observed in iPD while both LC3II and phosphorylated ULK1 levels
showed a very strong inverse correlation with disease duration in
G2019S cases suggesting that disease severity may correlate with
dysregulation of autophagy (Supplementary Table S2). These results
overall highlight a divergent autophagic signature of G2019S PD
cases that may correlate with synuclein aggregation and examina-
tion of further cases and controls is warranted to address this.
To further characterize the autophagic signature of the G2019S
PD cases the expression and distribution of p62 was investigated
by immunostaining. The iPD and G2019S PD cases were classified
as having the limbic sub-type distribution of a-synuclein
pathology and were described previously (Mamais et al., 2013).
p62 was detected in PBs and LBs in both idiopathic and LRRK2 PDcohorts in the s.nigra. Lower numbers of p62-positive Lewy neurites
were detected in G2019S PD compared to iPD cases. p62 was also
detected in GVDs, which can form as a result of defective autolyso-
some formation (Funk et al., 2011). Interestingly, higher numbers of
p62-positive GVDs were detected in G2019S PD compared to spo-
radic cases. The immunoblot data from LAMP1, LC3 and ULK1 were
consistent with the IH data (Fig. 2).We did not observe any LC3 pos-
itive LBs, in contrast to a recent report (Higashi et al., 2011).
The role of LRRK2 in vesicular trafficking has gained substantial
interest in recent years. LRRK2 can associate and directly phospho-
rylate a subgroup of small Rab GTPases, involved in regulating the
specificity and directionality of membrane trafficking processes
(Steger et al., 2016). LRRK2 associates with Rab29/Rab7L1 mediat-
ing trans-Golgi clustering and clearance of trans-Golgi-derived
vesicles and this is affected by PD-linked mutations on LRRK2
(Beilina et al., 2014). Furthermore, LRRK2 and Rab29/Rab7L1 con-
trol the integrity of the endolysosomal protein degradation process
in a common pathway that is affected by PD-linked mutations
(Fujimoto et al., 2018; MacLeod et al., 2013; Puriyte et al., 2018;
Zhiyong et al., 2018). LRRK2 KO mice display a biphasic alteration
of autophagic markers with age, with lower levels of p62 at 7
months old and higher levels at 20 months old compared to WT
mice (Tong et al., 2012). It is possible that an effect of LRRK2 on
macroautophagy as seen by altered LC3-II or p62 levels is a result
of dysregulated targeting of lysosomal components to the
autolysosome. The hypothesis of dysregulated lysosomal biogene-
sis is supported by lysosomal enlargement and a deficit in recruit-
ment of lysosomal hydrolases seen in rat primary neurons
expressing G2019S LRRK2 (MacLeod et al., 2013). The lysosomal
protein LAMP1 is transported from the trans-Golgi network to
lysosomes where it mediates lysosomal maturation, fusion with
autophagosomes and degradation of cargo (Saftig and
Klumperman, 2009). Phosphorylation of p62 by LRRK2 has been
reported recently, and it may provide a context to explain the
autophagic differences we observe between iPD and G2019S tissue.
According to Kalogeropoulou and colleagues (Kaleogeropulou
et al., 2018), LRRK2 mutations induce cellular toxicity synergisti-
cally with p62 and dependent on p62 T138 phosphorylation. If
LRRK2-mediated phosphorylation of p62 induces p62-mediated
macroautophagy this may be reflected by altered protein levels
in post-mortem tissue driven by the G2019S hyperactive variant,
and would certainly underlie a divergent autophagic signature
compared to iPD. Furthermore, mutations in p62 in amyotrophic
lateral sclerosis has been identified recently (Teyssou et al., 2013)
implying the importance of autophagy regulation in neurodegen-
eration. Finally, recent data from our group has shown that chronic
LRRK2 kinase inhibition imparts mTOR independent alteration in
ULK1 phosphorylation in astrocyte cultures further reiterating
the importance of autophagy regulation in the context of LRRK2
pathobiology (Manzoni et al., 2018).
The data presented in this study demonstrate decreased levels
of LAMP1 in the basal ganglia of G2019S mutation carriers com-
pared to iPD and control cases, and are consistent with a model
of impairment of lysosomal targeting in LRRK2 PD. Collectively,
our results support a distinct molecular signature for LRRK2 PD
compared to idiopathic disease, where dysregulation of vesicular
trafficking and sequestration of lysosomal components underpins
alterations in macroautophagy and protein clearance. A significant
caveat to these conclusions is the limited number of samples avail-
able for inclusion in this study. Although care was taken to match
genetically defined mutation carrier samples to idiopathic cases
and controls, as demonstrated by the extensive statistical analysis
undertaken (Supplementary Tables S1 and S2), it is not possible to
eliminate or completely control for the intrinsic variability
observed in human pathological samples. Analysis of further cases,
therefore, and in particular from patients with LRRK2 mutations
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resolution to the nature of the changes in autophagy in the brains
of individuals with LRRK2 associated PD. In this context, it is of
interest to note that LRRK2 levels are increased in early stages of
iPD (Dzamko et al., 2017), but are reduced in LRRK2 mutation cases
(Zhao et al., 2018). It is also important to note that this study ana-
lyzed the situation in the brain post mortem, and is therefore
unavoidably static in nature – precluding the possibility of an
examination of autophagic flux. As such, and due to the dynamic
nature of macroautophagy, it is not possible to discriminate
between alterations in induction of macroautophagy and changes
in fusion with the lysosomes and recycling of autophagic vesicles.
To achieve this, further investigations in animal and cellular mod-
els for LRRK2 function will be required.
4. Experimental procedure
4.1. Case details and tissue collection
The post-mortem human brain tissues used were previously
described (Mamais et al., 2013; Khan et al., 2005). All 14 cases were
obtained from the Queen Square Brain Bank. Appropriate consent
was obtained and approval for this study was granted by the local
Research Ethics Committee. Neuropathological classification was
of the limbic sub-type for a-synuclein pathology in all G2019S
PD cases (McKeith et al., 2005). The cumulated demographics of
the cases used are provided in Supplementary Table S1. Alpha-
synuclein pathology matched iPD cases were used and the controls
had no observable neuropathology or clinically diagnosed neuro-
logical disease. All PD cases showed slow progressive parkinsonism
with good levodopa response. Flash frozen tissue was obtained
from the basal ganglia (caudate and putamen), and formalin fixed
tissue blocks from s.nigra, basal ganglia, amygdala (part of limbic
cortex), and frontal cortex were used for immunohistochemistry.
It is important to note that our control and iPD cases investigated
here were negative for G2019S mutation.
4.2. Differential ultracentrifugation and fractionation
Tissue was processed as described (Mamais et al., 2013;
Bandopadhyay, 2016). Briefly, 10% (w/v) homogenates were pre-
pared from 1 g tissue from the basal ganglia in homogenization
buffer [20 mM Tris–HCl pH 7.4, 150 mM NaCl, protease and phos-
phatase inhibitors (ROCHE)] and cleared by centrifugation at
1000g, 5 min, 4 C. The cleared homogenate was centrifuged at
100,000g, 1 h, 4 C to produce the TBS-soluble fraction (super-
natant). The pellet was washed and resuspended by sonication in
2.5 ml homogenization buffer supplemented with 5% (w/v) SDS,
and centrifuged at 100,000g, for 30 min, at 16 C to produce the
SDS-soluble fraction (supernatant).
4.3. Antibodies used
The following antibodies: p62 (BD Biosciences 610833), LAMP1
(ABCAM, ab25630), LC3 (Novus, NB100-2220), b-actin (Sigma,
clone AC-40), pS758 ULK1 (Cell Signaling, 6888), and ULK1 (Cell
Signaling, 8054) were used for both immunoblots and IH protocols.
These antibodies are extensively characterized for use in both tech-
niques as mentioned in manufacturer’s websites and some are
characterized against the corresponding knock-out tissue.
4.4. Immunoblotting
30 lg of each sample were analyzed by western blotting, using
standard techniques and as described previously (Mamais et al.,
2013). Results of individual autophagy markers are expressed rel-ative to b-actin used as a housekeeping marker. The statistical test
used for immunoblots were one-way ANOVA with Tukey’s post-
hoc correction as indicated in the text.
4.5. qRT-PCR of autophagy markers
Small chunks of basal ganglia were homogenized and RNA was
extracted using Trizol reagent (Thermo Fisher), as per manufactur-
ers instructions. RNA concentration and purity was measured spec-
trophotometrically using a Nanodrop (Thermo scientific). All RNA
samples had an A260/A280 ratio above 1.9. 1 lg of RNA was
reverse transcribed using superscriptIV (Thermo Fisher) using ran-
dom hexamer primers. qPCR was performed using Power SYBR
green master mix (Thermo Fisher) and a Stratagene Mx3000P
cycler (Agilent). The primer pairs used were RPL19a Forward:
50CCCACAACATGTACCGGGAA30; RPL19a Reverse: 50TCT
TGGAGTCGTGGAACTGC30; SQSTM1 (p62) Forward: 50CCTC
CTAACAAGTGTATCTC30, SQSTM1 (p62) Reverse: 50ACGACTA
TGTGACCTCTT30; LAMP1 Forward: 50CATACACTCACTCTCAAT30,
LAMP1 Reverse 50ATGTCAGTTATAGATTCCA30; ULK1: Forward:
50GTCACACGCCACATAACAG30; ULK1 Reverse: 50TCTTCTAAGT
CCAAGCACAGT30; LC3B: Forward: 50AGTAGTTATCACTCTTAGG30;
LC3B Reverse: 50CTCTTGACATTAGTATCTG30. The cycling protocol
consisted of an initial denaturation of 95C for 10 min followed by
40 cycles involving denaturation at 95C for 30sec followed by
annealing for 60sec at 60C and extension for 60sec at 72C. A disso-
ciation curve was added at the end to confirm a single amplicon.
All samples were amplified in duplicates. Data were generated
using the deltaCT methods and results were normalized to the ref-
erence gene RPL19a and relative expression to one control brain
sample (Pfaffl, 2001).
4.6. Immunohistochemistry
Standard immunohistochemistry protocols were followed as
described previously (Mamais et al., 2013). Briefly, formalin-fixed
tissue sections from s. nigra, basal ganglia, amygdala and frontal
cortex were immersed in methanol containing 0.3% H2O2 to
quench endogenous peroxidase activity and pretreated with pres-
sure cooking in 10 mM citrate buffer at pH 6.0 for 10 min to expose
antigenic sites. Sections were then blocked in 10% milk for 1 hr and
incubated with mouse monoclonal primary antibody to p62
(BD transduction laboratory) at 1:300; LAMP-1 (1:200); LC3
1:100; ULK1 1:100 dilution, overnight at 4 C. Following biotiny-
lated secondary antibody (DAKO) administration, the sections
were washed and incubated with the avidin-biotinylated enzyme
complex and finally visualized with hydrogen peroxide (0.05%)
activated 3,30-diaminobenzidine chromogen. Sections were lightly
counterstained with Meyer’s haematoxylin, dehydrated in graded
alcohols, cleared in xylene and cover slipped in DPX mounting
medium (BDH). All sections were stained twice with similar
results. Negative controls by omitting the primary and secondary
antibodies were run concurrently for each antibody.
4.7. Semi-quantitative scoring of p62 inclusions and IH scores of
Lamp1, LC3 and ULK1.
A four-point scoring system was employed to score for number
of p62 positive inclusions similar to that employed previously by
our group (Mamais et al., 2013; Sharma et al., 2011). Scoring was
carried out independently by two researchers (RB and IN) and
the consensus results are presented. All p62 scores were done at
X20 objective. Score ‘‘-/0” is equivalent to absence of staining or
no inclusions; ‘‘+/1” = occasional staining or up to 2 inclusions;
‘‘++/2” = moderate staining or between 3 and 10 p62 inclusions
and ‘‘+++/3” = large number of neurons showing p62 staining or
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semiquantitaive assessments of DAB immunohistochemistry for
LAMP1, LC3 and ULK1 were done on a 4-point grading scale: 0 indi-
cates no staining (neuronal or glial) that could be considered to be
above background level; 1 indicates few cells (2+) (neuronal or
glial) lightly stained, 2 indicates that most cells (neuronal and glial)
moderately stained and 3 indicates most/all (neuronal or glial)
cells strongly stained. Pooled scores from neurons and glia staining
were analysed using Kruskall Wallis test followed by Dunn’s mul-
tiple comparison analysis.
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